Hepatitis C and Innate Immunity: Recent Advances

Clinics in Liver Disease

Volumn 12, Issue 3, 2008, Pages 675-692

  Szabo, Gyongyi ^a   Dolganiuc, Angela ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CPG 10101; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 19; INTERLEUKIN 20; ISATORIBINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PEGINTERFERON; PROTEIN LGP2; PROTEIN MDA5; REGULATOR PROTEIN; RESIQUIMOD; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; RNA HELICASE; STAT PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADAPTIVE IMMUNITY; ALCOHOL LIVER CIRRHOSIS; ANTIGEN PRESENTATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CHRONIC HEPATITIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; HEPATITIS C; HEPATOMA CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; INNATE IMMUNITY; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, NATURAL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 46749128497     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.003     Document Type: Review

References (115)

1. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
2. Pawlotsky J.M. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 44 1 Suppl (2006) S10-S13 Epub 2005 Nov 21
3. Kaisho T., and Akira S. Critical roles of Toll-like receptors in host defense. Crit Rev Immunol 20 5 (2000) 393-405
4. Barton G.M. Viral recognition by Toll-like receptors. Semin Immunol 19 1 (2007) 33-40
5. Bowie A.G., and Fitzgerald K.A. RIG-I: tri-ing to discriminate between self and non-self RNA. Trends Immunol 28 4 (2007) 147-150
6. Kawai T., and Akira S. TLR signaling. Semin Immunol 19 1 (2007) 24-32
7. Colonna M. TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol 37 2 (2007) 306-309
8. Yoneyama M., and Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem 282 21 (2007) 15315-15318
9. Rothenfusser S., Goutagny N., DiPerna G., et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 175 8 (2005) 5260-5268
10. Yoneyama M., Kikuchi M., Matsumoto K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175 5 (2005) 2851-2858
11. Kato H., Takeuchi O., Sato S., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 7089 (2006) 101-105
12. Saito T., Hirai R., Loo Y.M., et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 104 2 (2007) 582-587
13. Li K., Chen Z., Kato N., et al. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 280 17 (2005) 16739-16747
14. Dansako H., Ikeda M., and Kato N. Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes. FEBS J 274 16 (2007) 4161-4176
15. Binder M., Kochs G., Bartenschlager R., et al. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46 5 (2007) 1365-1374
16. Meylan E., Curran J., Hofmann K., et al. Cardif is an adaptor protein in the RIG-1 antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
17. Xu L.G., Wang X.Y., Han K.J., et al. VISA is an adaptor protein required for virus-triggered IFN-beta signaling. Mol Cell 19 (2005) 727-740
18. Seth R.B., Sun L., Ea C.K., et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NFkappaB and IRF 3. Cell 122 5 (2005) 669-682
19. Kawai T., Takahashi K., Sato S., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6 (2005) 981-988
20. Meylan E., Tschopp J., and Karin M. Intracellular pattern recognition receptors in the host response. Nature 442 7098 (2006) 39-44
21. Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 12 (2006) 167-176
22. Hemmi H., Kaisho T., Takeuchi O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
23. Diebold S.S., Kaisho T., Hemmi H., et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
24. Hornung V., Guenthner-Biller M., Bourquin C., et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11 3 (2005) 263-270
25. Liu S., Gallo D., Green A., et al. Role of TLRs in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with LPS. Infect Immun 70 (2002) 3433-3442
26. Nishimura M., and Naito S. Tissue-specific mRNA expression profiles of human TLRs and related genes. Biol Pharm Bull 28 (2005) 886-892
27. Szabo G., Dolganiuc A., and Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44 (2006) 287-298
28. Ito T., Amakawa R., and Fukuhara S. Roles of Toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum Immunol 63 (2002) 1120-1125
29. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 (2007) 39-45
30. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
31. Gorden K.B., Gorski K.S., Gibson S.J., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174 (2005) 1259-1268
32. Assier E., Marin-Esteban V., Haziot A., et al. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J Leukoc Biol 81 (2007) 221-228
33. Dolganiuc A., Kodys K., Kopasz A., et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 170 11 (2003) 5615-5624
34. Gay N.J., and Keith F.J. Drosophila Toll and IL-1 receptor. Nature 351 (1991) 355-356
35. Umeatsu S., Sato S., Yamamoto M., et al. IRAK-1 plays an essential role for TLR7- and TLR9-mediated IFN-a induction. J Exp Med 201 (2005) 915-923
36. Sato M., Hata N., Asagiri M., et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441 (1998) 106-110
37. Sugimoto K., Stadanlick J., Ikeda F., et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37 3 (2003) 590-599
38. Thimme R., Oldach D., Chang K.M., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 10 (2001) 1395-1406
39. Chang K.M., Thimme R., Melpolder J.J., et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 1 (2001) 267-276
40. Chang K.M., Gruener N.H., Southwood S., et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162 2 (1999) 1156-1164
41. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
42. Thimme R., Bukh J., Spangenberg H.C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 99 24 (2002) 15661-15668
43. Cox A.L., Mosbruger T., Lauer G.M., et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 1 (2005) 104-112
44. Cooper S., Erickson A.L., Adams E.J., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
45. Oleksyk T.K., Thio C.L., Truelove A.L., et al. Single nucleotide polymorphisms and haplotypes in the IL-10 region associated with HCV clearance. Genes Immun 6 4 (2005) 347-357
46. Foy E., Ferreon J.C., Nakamura M., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102 8 (2005) 2992-2997
47. Li X.D., and Sun L. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102 (2005) 17717-17722
48. Breiman A., Vitour D., Vilasco M., et al. A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells. J Gen Virol 87 (2006) 3587-3598
49. Breiman A., Grandvaux N., Lin R., et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 79 7 (2005) 3969-3978
50. Vilasco M., Larrea E., Vitour D., et al. The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers. Hepatology 44 6 (2006) 1635-1647
51. Johnson C.L., Owen D.M., and Gale Jr. M. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 282 14 (2007) 10792-10803
52. Abe T., Kaname Y., Hamamoto I., et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 81 17 (2007) 8953-8966
53. Duesberg U., von dem Bussche A., Kirschning C., et al. Activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol Lett 84 2 (2002) 89-95
54. Szabo G., and Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 210 2-4 (2005) 237-247
55. Pham T.N., MacParland S.A., and Mulrooney P.M. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78 11 (2004) 5867-5874
56. Rodrigue-Gervais I.G., Jouan L., Beaule G., et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J Virol 81 11 (2007) 5537-5546
57. Wertheimer A.M., Polyak S.J., Leistikow R., et al. Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology 45 6 (2007) 1422-1432
58. He Q., Graham C.S., Durante Mangoni E., et al. Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver Int 26 9 (2006) 1100-1110
59. Taylor M.W., Tsukahara T., Brodsky L., et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81 7 (2007) 3391-3401
60. Schott E., Witt H., Neumann K., et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 47 2 (2007) 203-211
61. Cao W., and Liu Y.J. Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol 19 1 (2007) 24-30
62. Yonkers N.L., Rodriguez B., Milkovich K.A., et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 178 7 (2007) 4436-4444
63. Dolganiuc A., Chang S., Kodys K., et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 177 10 (2006) 6758-6768
64. Wertheimer A.M., Bakke A., and Rosen H.R. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40 2 (2004) 335-345
65. Nattermann J., Zimmermann H., Iwan A., et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 44 4 (2006) 945-954
66. Bowen D.G., McCaughan G.W., and Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol 26 10 (2005) 512-517
67. Racanelli V., and Rehermann B. The liver as an immunological organ. Hepatology 43 2 Suppl 1 (2006) S54-S62
68. Lai W.K., Curbishley S.M., Goddard S., et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatol 47 3 (2007) 338-347
69. Lai W.K., Sun P.J., Zhang J., et al. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol 169 1 (2006) 200-208
70. Averill L., Lee W.M., and Karandikar N.J. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol 123 1 (2007) 40-49
71. Tsubouchi E., Akbar S.M., Horiike N., et al. Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection. J Gastroenterol 39 8 (2004) 754-762
72. Pachiadakis I., Pollara G., Chain B.M., et al. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?. Lancet Infect Dis 5 5 (2005) 296-304
73. Laporte J., Bain C., Maurel P., et al. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 101 1 (2003) 52-57
74. Aloman C., Gehring S., Wintermeyer P., et al. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology 132 2 (2007) 698-708
75. Hiasa Y., Takahashi H., Shimizu M., et al. Major histocompatibility complex class-I presentation impaired in transgenic mice expressing hepatitis C virus structural proteins during dendritic cell maturation. J Med Virol 74 2 (2004) 253-261
76. Auffermann-Gretzinger S., Keeffe E.B., and Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97 10 (2001) 3171-3176
77. Kanto T., Hayashi N., Takehara T., et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162 9 (1999) 5584-5591
78. Bain C., Fatmi A., Zoulim F., et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120 2 (2001) 512-524
79. Gelderblom H.C., Nijhuis L.E., de Jong E.C., et al. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int 27 7 (2007) 944-953
80. MacDonald A.J., Semper A.E., Libri N.A., et al. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol 148 3 (2007) 494-500
81. Larsson M., Babcock E., Grakoui A., et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 78 12 (2004) 6151-6161
82. Longman R.S., Talal A.H., Jacobson I.M., et al. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 192 3 (2005) 497-503
83. Longman R.S., Talal A.H., Jacobson I.M., et al. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103 3 (2004) 1026-1029
84. Piccioli D., Tavarini S., Nuti S., et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42 1 (2005) 61-67
85. Rollier C., Drexhage J.A., Verstrepen B.E., et al. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment. Hepatology 38 4 (2003) 851-858
86. Barnes E., Salio M., Cerundolo V., et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 48 9 (2004) 3382-3389
87. Miyatake H., Kanto T., Inoue M., et al. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J Viral Hepat 14 6 (2007) 404-412
88. Lee S.H., Miyagi T., and Biron C.A. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol 28 6 (2007) 252-259
89. Larkin J., Bost A., Glass J.I., et al. Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. J Interferon Cytokine Res 26 12 (2006) 854-865
90. Larkin J., Jin L., Farmen M., et al. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 23 5 (2003) 247-257
91. Crotta S., Ronconi V., Ulivieri C., et al. Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol 36 4 (2006) 919-929
92. Crotta S., Stilla A., Wack A., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195 1 (2002) 35-41
93. Jinushi M., Takehara T., Tatsumi T., et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173 10 (2004) 6072-6081
94. Jinushi M., Takehara T., Tatsumi T., et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 171 10 (2003) 5423-5429
95. Lechmann M., Woitas R.P., Langhans B., et al. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 31 6 (1999) 971-978
96. Godkin A., Jeanguet N., Thursz M., et al. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunol 31 5 (2001) 1438-1446
97. De Maria A., Fogli M., Mazza S., et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 37 2 (2007) 445-455
98. Golden-Mason L., and Rosen H.R. Natural killer cells: primary target for hepatitis C virus immune evasion strategies?. Liver Transpl 12 3 (2006) 363-372
99. Szabo G., and Dolganiuc A. HCV immunopathogenesis: virus-induced strategies against host immunity. Clin Liver Dis 10 4 (2006) 753-771
100. Chang S., Dolganiuc A., and Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 82 3 (2007) 479-487
101. Riordan S.M., Skinner N.A., Kurtovic J., et al. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 55 7 (2006) 279-285
102. Eid A.J., Brown R.A., Paya C.V., et al. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 84 4 (2007) 511-516
103. Dolganiuc A., Oak S., Kodys K., et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127 5 (2004) 1513-1524
104. Wisniewska-Ligier M., Wozniakowska-Gesicka T., Glowacka E., et al. Involvement of innate immunity in the pathogenesis of chronic hepatitis C in children. Scand J Immunol 64 4 (2006) 425-432
105. Mozer-Lisewska I., Sluzewski W., Kaczmarek M., et al. Tissue localization of Toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus. Scand J Immunol 62 4 (2005) 407-412
106. Lederer S.L., Walters K.A., Proll S., et al. Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. Virol J 3 (2006) 98
107. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117 3 (2007) 539-548
108. DeMinicis S., Bataller R., and Brenner D.A. NADPH oxidase in the liver: defensive, offensive, or fibrogenic?. Gastroenterology 131 1 (2006) 272-275
109. Maki A., Kono H., Gupta M., et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 14 3 (2007) 1182-1190
110. Matsuzaki K., Murata M., Yoshida K., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46 1 (2007) 48-57
111. Horsmans Y., Berg T., Desager J.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42 3 (2005) 724-731
112. Pockros P.J., Schiff E.R., Shiffman M.L., et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46 2 (2007) 324-329
113. Pockros P.J., Guyader D., Patton H., et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47 2 (2007) 174-182
114. Vicari A.P., Schmalbach T., Lekstrom-Himes J., et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILOM), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 12 5 (2007) 741-751
115. Thomas A., Laxton C., Rodman J., et al. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 31 8 (2007) 2969-2978